e-Article
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab
Document Type
Article
Author
Chandrakasan, Shanmuganathan; Jordan, Michael B.; Baker, Ashley; Behrens, Edward M.; Bhatla, Deepika; Chien, May; Eckstein, Olive S.; Henry, Michael M.; Hermiston, Michelle L.; Hinson, Ashley P.; Leiding, Jennifer W.; Oladapo, Abiola; Patel, Sachit A.; Pednekar, Priti; Ray, Anish K.; Dávila Saldaña, Blachy; Sarangi, Susmita N.; Walkovich, Kelly J.; Yee, John D.; Zoref-Lorenz, Adi; Allen, Carl E.; Weinstein, Joanna; Hinson, Ashley P.; Allen, Carl E.; Eckstein, Olive S.; Gulati, Nitya; Chandrakasan, Shanmuganathan; Haines, Hilary; Nakano, Taizo; Patel, Sachit A.; Behrens, Edward M; Intzes, Stefanos; Hays, Allyson; Dávila Saldaña, Blachy; Jordan, Michael B.; Zoref-Lorenz, Adi; Hanna, Rabi; Isakoff, Michael; Ray, Anish K.; Rothman, Jennifer; Tandra, Anand; Cooper, Robert; Leiding, Jennifer W.; Chien, May; Sarangi, Susmita; Gidvani, Diaz; Satwani, Prakesh; Carter, John; Henry, Michael; Gloude, Nicholas; Bhatt, Sima; Bhatla, Deepika; Draper, Lauren; Panigrahi, Arun; Hermiston, Michelle; Modica, Renee; Riskalla, Mona; Baker, Ashley; Ward, Brant
Source
Blood Advances; May 2024, Vol. 8 Issue: 9 p2248-2258, 11p
Subject
Language
ISSN
24739529; 24739537
Abstract
•Addition of emapalumab improves laboratory parameters and overall survival in patients with pHLH in real-world clinical practice.•Addition of emapalumab provides an effective bridge to HSCT in evaluable patients with pHLH in real-world clinical practice.